Neurology

Do SGLT2 inhibitors lower the risk of cognitive decline?

September 20, 2024

SGLT2i use was associated with significantly reduced risk of neurodegenerative disorders in patients with T2DM, independent of other factors.

• This Korean population-based cohort study examined the association between SGLT2i use and risks of incident dementia and Parkinson disease (PD) in patients with T2DM.
• Among 358,862 participants (mean age, 57.8 years; 58.0% male), 6,837 incident dementia or PD events were recorded. SGLT2i use was associated with reduced risks of Alzheimer disease (adjusted hazard ratio [aHR] 0.81), vascular dementia (aHR 0.69), and PD (aHR 0.80) with a 6-month drug use lag period.
• SGLT2i users had a 21% lower risk of developing all-cause dementia and a 22% lower risk of developing all-cause dementia and PD compared with those using other oral antidiabetic drugs (aHR 0.78). The association between SGLT2i use and risk of neurodegenerative disorders wasn't affected by sex or other bioclinical parameters (e.g., BP, glucose, lipid profiles).

Source:

Kim HK, et al. (2024, October 22). Neurology. SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes. https://pubmed.ncbi.nlm.nih.gov/39292986/